Edition:
United States

Theravance Biopharma Inc (TBPH.OQ)

TBPH.OQ on NASDAQ Stock Exchange Global Market

28.24USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$28.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
87,522
52-wk High
$43.30
52-wk Low
$23.18

Select another date:

Thu, Nov 16 2017

BRIEF-Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD

* Theravance Biopharma highlights marketing authorization in Europe for Trelegy Ellipta as once-daily single inhaler triple therapy for the treatment of COPD Source text for Eikon: Further company coverage:

BRIEF-Theravance Biopharma and Mylan submit marketing application to FDA for revefenacin

* Theravance Biopharma and Mylan submit new drug application to FDA for revefenacin (TD-4208) in adults with chronic obstructive pulmonary disease

BRIEF-Theravance Biopharma posts Q3 loss of $1.27 per share

* Theravance biopharma, inc. Reports third quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma and Mylan reports positive Phase 3 data for Revefenacin

* Theravance Biopharma and mylan report additional positive phase 3 data for Revefenacin (TD-4208) in multiple presentations at 2017 Chest Annual Meeting

BRIEF-Theravance Biopharma reports positive new data from multiple studies of VIBATIV at IDWeek 2017

* Theravance Biopharma reports positive new data from multiple studies of VIBATIV (telavancin) at IDWeek 2017

BRIEF-Theravance Biopharma highlights positive results from impact study of Trelegy Ellipta

* Theravance Biopharma highlights positive headline results from impact study of Trelegy Ellipta announced by Glaxosmithkline and Innoviva

BRIEF-Theravance Biopharma highlights approval of trelegy ellipta for treatment of appropriate patients with COPD in the U.S.

* Theravance Biopharma highlights approval of trelegy ellipta (closed triple) as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US

BRIEF-Theravance Biopharma reports Q2 revenue of $3.5 mln

* Reports second quarter 2017 financial results and provides business update

BRIEF-Theravance Biopharma announces positive top-line results from phase 2B study of velusetrag

* Theravance Biopharma announces positive top-line results from phase 2B study of Velusetrag (TD-5108) in patients with gastroparesis

BRIEF-Theravance Biopharma and Mylan announce positive results from 12-month phase 3 safety study of revefenacin

* Theravance Biopharma and Mylan announce positive results from 12-month phase 3 safety study of revefenacin (TD-4208) in patients with chronic obstructive pulmonary disease (COPD)

Select another date: